John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses long-term safety data with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.
Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the significance of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.
Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.
Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.
Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.
Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).
Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).
Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses prevention in head and neck cancer.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the shifting landscape of kidney cancer.
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses biomarkers in endometrial cancer.
Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).
Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the need for new treatment strategies in colorectal cancer.
Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).
Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.
Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.
Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.
Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).
